The Experts below are selected from a list of 249 Experts worldwide ranked by ideXlab platform
Robert A. Cormier - One of the best experts on this subject based on the ideXlab platform.
-
Shunt surgery versus Endoscopic Sclerotherapy for variceal hemorrhage: Late results of a randomized trial
American journal of surgery, 1993Co-Authors: Layton F. Rikkers, Gongliang Jin, David A. Burnett, Kenneth N. Buchi, Robert A. CormierAbstract:Between September 1982 and April 1988, 60 cirrhotic patients with prior variceal hemorrhage were randomized to undergo the placement of an elective shunt (distal splenorenal: 26; nonselective: 4) or long-term Endoscopic Sclerotherapy (n=30). Eighty-six percent of patients had alcoholic cirrhosis, and 33% were classified as Child's class C. After a mean follow-up of 87 months, 60% of patients undergoing Sclerotherapy and 17% of shunt patients experienced rebleeding (p In a predominantly alcoholic cirrhotic patient population (half non-urban), the results of elective shunt surgery were superior to those of chronic Endoscopic Sclerotherapy with respect to the prevention of recurrent variceal hemorrhage and survival.
Shiyao Chen - One of the best experts on this subject based on the ideXlab platform.
-
Transparent cap-assisted Endoscopic Sclerotherapy in esophageal varices: a randomized-controlled trial.
European journal of gastroenterology & hepatology, 2018Co-Authors: Xiaoquan Huang, Jing-jing Lian, Jian Wang, Shiyao ChenAbstract:Background and aim Endoscopic treatment is widely accepted as the first-line therapy selection for esophageal variceal bleeding. Nevertheless, Endoscopic injection Sclerotherapy requires experienced endoscopists and is associated with a high risk of bleeding. Our study evaluates the feasibility and efficacy of transparent cap-assisted Endoscopic Sclerotherapy in the management of esophageal varices. Patients and methods A randomized-controlled trial was conducted in a tertiary referral center from April 2015 to May 2016. Patients who received Endoscopic Sclerotherapy were randomized in a blinded manner into two groups: the transparent cap-assisted group (n=59) and the control group (n=61). Results The average injection sites were reduced in the transparent cap-assisted group compared with the control group (1.2±0.4 vs. 1.4±0.05, P=0.000), whereas no difference was observed in the dosage of lauromacrogol (16.97±4.91 vs. 16.85±4.57, P=0.662) and the hemorrhage that occurred during injection made no difference (50.8 vs. 61.0%, P=0.276); yet, salvage hemostasis methods were used in only nine patients in the transparent cap-assisted group compared with 17 patients in the control group (25.0 vs. 38.7%, P=0.0936). The cost of each procedure in the cap-assisted group was ¥2578 (1878-4202), whereas it was ¥3691 for the control group (2506-5791) (P=0.023). Moreover, in both groups, no esophageal constriction was observed during the 6-month follow-up period, whereas the rebleeding rate between two groups showed no statistical significance in 6 months (89.8 vs. 93.4%, P=0.563). Conclusion Transparent cap-assisted Sclerotherapy provided a clear field of vision and helped to fix the targeted veins, thus significantly reducing the use of the salvage hemostasis method during Sclerotherapy injection hemorrhage. It is also associated with reduced injection sites and Endoscopic therapy cost.
Layton F. Rikkers - One of the best experts on this subject based on the ideXlab platform.
-
Shunt surgery versus Endoscopic Sclerotherapy for variceal hemorrhage: Late results of a randomized trial
American journal of surgery, 1993Co-Authors: Layton F. Rikkers, Gongliang Jin, David A. Burnett, Kenneth N. Buchi, Robert A. CormierAbstract:Between September 1982 and April 1988, 60 cirrhotic patients with prior variceal hemorrhage were randomized to undergo the placement of an elective shunt (distal splenorenal: 26; nonselective: 4) or long-term Endoscopic Sclerotherapy (n=30). Eighty-six percent of patients had alcoholic cirrhosis, and 33% were classified as Child's class C. After a mean follow-up of 87 months, 60% of patients undergoing Sclerotherapy and 17% of shunt patients experienced rebleeding (p In a predominantly alcoholic cirrhotic patient population (half non-urban), the results of elective shunt surgery were superior to those of chronic Endoscopic Sclerotherapy with respect to the prevention of recurrent variceal hemorrhage and survival.
Joan Antoni Salvá - One of the best experts on this subject based on the ideXlab platform.
-
Portacaval shunt versus Endoscopic Sclerotherapy in the elective treatment of variceal hemorrhage.
Gastroenterology, 1991Co-Authors: Ramon Planas, Jaume Boix, M. Broggi, Eduard Cabré, Maria Cristina Gomes-vieira, Rosa Maria Morillas, M. Armengol, Rosa De León, P. Humbert, Joan Antoni SalváAbstract:Abstract Eighty-two consecutive Child-Campbell class A and B cirrhotic patients were included in a prospective controlled trial to assess the efficacy and safety of portacaval anastomosis vs. Endoscopic Sclerotherapy as elective treatment of variceal hemorrhage. Forty-one patients were randomized to portacaval anastomosis and 41 to Sclerotherapy. After excluding dropouts, 34 patients were treated with portacaval anastomosis and 35 with Sclerotherapy. The incidence of variceal rebleeding during follow-up (mean ± SD, 20.6 ± 14.2 months) was significantly higher in the Sclerotherapy than in the portacaval groups, either considering the overall treated group or only patients completing Sclerotherapy (40% and 25% vs. 2.9%; P = 0.0002 and P = 0.01, respectively). The 2-year probability of suffering from at least one episode of hepatic encephalopathy was significantly higher in patients submitted to portacaval anastomosis than in those treated with Endoscopic Sclerotherapy (40% vs. 12%; P = 0.04). However, disabling encephalopathy only appeared in 3 of 34 patients who underwent surgery (8.8%). Early and long-term mortality did not differ between the therapeutic groups; 2-year survival rates were 83% for portacaval anastomosis and 79% for Sclerotherapy. It is concluded that portacaval anastomosis is more effective than Endoscopic Sclerotherapy in preventing variceal rebleeding in spite of the greater incidence of hepatic encephalopathy. The role of portacaval anastomosis in the elective treatment of variceal rebleeding should be reassessed.
Gongliang Jin - One of the best experts on this subject based on the ideXlab platform.
-
Shunt surgery versus Endoscopic Sclerotherapy for variceal hemorrhage: Late results of a randomized trial
American journal of surgery, 1993Co-Authors: Layton F. Rikkers, Gongliang Jin, David A. Burnett, Kenneth N. Buchi, Robert A. CormierAbstract:Between September 1982 and April 1988, 60 cirrhotic patients with prior variceal hemorrhage were randomized to undergo the placement of an elective shunt (distal splenorenal: 26; nonselective: 4) or long-term Endoscopic Sclerotherapy (n=30). Eighty-six percent of patients had alcoholic cirrhosis, and 33% were classified as Child's class C. After a mean follow-up of 87 months, 60% of patients undergoing Sclerotherapy and 17% of shunt patients experienced rebleeding (p In a predominantly alcoholic cirrhotic patient population (half non-urban), the results of elective shunt surgery were superior to those of chronic Endoscopic Sclerotherapy with respect to the prevention of recurrent variceal hemorrhage and survival.